The rise of Viagra and its impact on the drug landscape presents a complex question for investors. While the initial sales data were remarkable, the exclusivity has lapsed, leading to a wave of off-brand alternatives that are chipping away at earnings. Moreover, the industry is facing issues related to population trends and shifting healthcare regu